Drug application
NOVRAD (LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS)
Drugs@FDA NDA 012928 · LILLY
Key facts
| Drug name | NOVRAD |
|---|---|
| Active ingredients | LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS |
| Application type | NDA |
| Application number | 012928 |
| Company | LILLY |
| Dosage forms | SUSPENSION, ORAL |
| Strength | EQ 50MG BASE/5ML |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 3 - New Dosage Form |
| Latest submission status date | Mar 21, 1962 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.